{"id":"maintenance-therapy-with-capecitabine","safety":{"commonSideEffects":[{"rate":"15-25","effect":"Hand-foot skin reaction"},{"rate":"15-20","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Fatigue"},{"rate":"10-15","effect":"Vomiting"},{"rate":"10-15","effect":"Stomatitis"},{"rate":"5-10","effect":"Myelosuppression"}]},"_chembl":{"chemblId":"CHEMBL1773","moleculeType":"Small molecule","molecularWeight":"359.35"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Capecitabine is an oral fluoropyrimidine carbamate that undergoes hepatic and tumor-selective conversion to 5-fluorouracil (5-FU). Once activated, 5-FU inhibits thymidylate synthase, blocking dTMP synthesis and DNA replication, while also incorporating into RNA to disrupt protein synthesis. This dual mechanism leads to cancer cell death, particularly in rapidly dividing cells.","oneSentence":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:42.726Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance therapy for colorectal cancer (likely indication based on capecitabine use)"},{"name":"Metastatic breast cancer"},{"name":"Gastric cancer"}]},"trialDetails":[{"nctId":"NCT05806060","phase":"PHASE3","title":"Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-04-25","conditions":"Triple-Negative Breast Cancer","enrollment":134},{"nctId":"NCT07471165","phase":"PHASE2","title":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Locally Advanced Perihilar Cholangiocarcinoma","enrollment":25},{"nctId":"NCT07446387","phase":"PHASE2","title":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":70},{"nctId":"NCT06532006","phase":"PHASE3","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2024-11-22","conditions":"Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer","enrollment":550},{"nctId":"NCT04605913","phase":"PHASE1, PHASE2","title":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-01","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07392320","phase":"PHASE2","title":"A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-04","conditions":"Nasopharangeal Cancer","enrollment":142},{"nctId":"NCT07383285","phase":"PHASE2","title":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02-01","conditions":"Rectal Neoplasms Malignant","enrollment":106},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":416},{"nctId":"NCT06739252","phase":"PHASE2","title":"Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA","status":"TERMINATED","sponsor":"Peking University","startDate":"2024-12-31","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Perihilar Cholangiocarcinoma","enrollment":1},{"nctId":"NCT07371910","phase":"PHASE3","title":"Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer, HRD-Positive/HER2-Negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT05807880","phase":"PHASE2","title":"Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-09-01","conditions":"Nasopharyngeal Neoplasms","enrollment":59},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07334431","phase":"PHASE1, PHASE2","title":"Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-02-22","conditions":"Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma","enrollment":45},{"nctId":"NCT07331428","phase":"PHASE2","title":"MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-01","conditions":"Nasopharyngeal Carcinoma, Local Recurrence","enrollment":25},{"nctId":"NCT04721977","phase":"PHASE2","title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-04-08","conditions":"Breast Cancer","enrollment":66},{"nctId":"NCT06332079","phase":"PHASE2","title":"Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2024-03-13","conditions":"Colorectal Cancer Metastatic","enrollment":4},{"nctId":"NCT05553522","phase":"PHASE1","title":"Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Baptist Health South Florida","startDate":"2024-01-29","conditions":"Brain Metastases, HER2-positive Breast Cancer","enrollment":1},{"nctId":"NCT06540326","phase":"PHASE2","title":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-11-12","conditions":"Colorectal Cancer Metastatic","enrollment":100},{"nctId":"NCT05249101","phase":"PHASE1, PHASE2","title":"A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CG Pharmaceuticals, Inc","startDate":"2022-08-15","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":70},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT05008783","phase":"PHASE3","title":"A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Akeso","startDate":"2021-09-17","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":610},{"nctId":"NCT03161522","phase":"PHASE2","title":"Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-19","conditions":"Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7","enrollment":100},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT07208526","phase":"NA","title":"A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Conversion Therapy, TDTP-RECIST","enrollment":270},{"nctId":"NCT05609370","phase":"PHASE1, PHASE2","title":"A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-29","conditions":"Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer","enrollment":113},{"nctId":"NCT07191405","phase":"NA","title":"Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-18","conditions":"Immunotherapy, Chemotherapy","enrollment":156},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT07177794","phase":"PHASE3","title":"Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-20","conditions":"Esophageal Cancer, Chemoradiotherapy","enrollment":242},{"nctId":"NCT04159142","phase":"PHASE2","title":"Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2019-11-20","conditions":"Triple Negative Breast Cancer, Nab-paclitaxel","enrollment":414},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT05775900","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2023-02-01","conditions":"Metastatic Colorectal Cancer","enrollment":24},{"nctId":"NCT07143097","phase":"PHASE2","title":"Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2021-11-01","conditions":"Triple -Negative Breast Cancer","enrollment":80},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT03828227","phase":"PHASE3","title":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2019-06-14","conditions":"Elderly Patients, Metastatic Colorectal Cancer, Quality of Life","enrollment":49},{"nctId":"NCT06992882","phase":"PHASE3","title":"A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-07-08","conditions":"HER2-positive Breast Cancer","enrollment":2306},{"nctId":"NCT07063888","phase":"PHASE2","title":"A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-05-16","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin","enrollment":66},{"nctId":"NCT07054879","phase":"","title":"CtDNA-guided Maintenance Therapy in Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-11-01","conditions":"Pancreatic Cancer","enrollment":70},{"nctId":"NCT07051785","phase":"PHASE2","title":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Liu Huang","startDate":"2025-07-07","conditions":"Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT07025174","phase":"PHASE2","title":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-06-01","conditions":"Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT07007728","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-06-01","conditions":"Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver","enrollment":54},{"nctId":"NCT06157996","phase":"PHASE2","title":"Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-06-01","conditions":"Gastric Cancer","enrollment":92},{"nctId":"NCT05141721","phase":"PHASE2, PHASE3","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seattle Project Corporation","startDate":"2022-02-12","conditions":"Colorectal Neoplasms","enrollment":700},{"nctId":"NCT06973343","phase":"PHASE2","title":"Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-05","conditions":"Colorectal Cancer Metastatic","enrollment":20},{"nctId":"NCT06093061","phase":"PHASE2","title":"Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2024-07-03","conditions":"Nasopharyngeal Carcinoma","enrollment":69},{"nctId":"NCT06742411","phase":"PHASE1, PHASE2","title":"XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-31","conditions":"Gastric (Stomach) Cancer","enrollment":57},{"nctId":"NCT04517214","phase":"PHASE2","title":"Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":100},{"nctId":"NCT05375708","phase":"PHASE2","title":"Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites","status":"SUSPENDED","sponsor":"UMC Utrecht","startDate":"2025-12-01","conditions":"Metastatic Colorectal Cancer, Oligometastatic Disease","enrollment":93},{"nctId":"NCT06888037","phase":"PHASE2","title":"Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-03-31","conditions":"Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy","enrollment":55},{"nctId":"NCT06858969","phase":"PHASE2","title":"Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-09","conditions":"Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT04627246","phase":"PHASE1","title":"Personalized Vaccine with SOC Chemo Followed by Nivo in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2020-09-11","conditions":"Pancreatic Adenocarcinoma","enrollment":14},{"nctId":"NCT06282445","phase":"PHASE2","title":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2024-03-01","conditions":"Colorectal Cancer Metastatic","enrollment":36},{"nctId":"NCT06578052","phase":"NA","title":"Irinotecan Liposome in Combination With Capecitabine","status":"RECRUITING","sponsor":"Junjie Hang","startDate":"2024-08-28","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT03916510","phase":"PHASE1","title":"Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-07-29","conditions":"Locally Advanced Rectal Cancer","enrollment":12},{"nctId":"NCT03117972","phase":"PHASE2","title":"Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2017-08-04","conditions":"Metastatic Colorectal Cancer","enrollment":54},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT06754059","phase":"","title":"Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC","status":"RECRUITING","sponsor":"zhangjie","startDate":"2021-06-01","conditions":"HER2-positive Breast Cancer","enrollment":60},{"nctId":"NCT05869227","phase":"PHASE3","title":"Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"XIANG YANQUN","startDate":"2023-04-28","conditions":"Nasopharyngeal Carcinoma, Maintenance Therapy","enrollment":166},{"nctId":"NCT06405490","phase":"PHASE2","title":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-04-17","conditions":"Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin","enrollment":30},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT04281576","phase":"NA","title":"Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"NovoCure Ltd.","startDate":"2019-12-19","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":28},{"nctId":"NCT06650332","phase":"PHASE1, PHASE2","title":"Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-07-10","conditions":"Metastatic HER2 Positive Gastroesophageal Junction Cancer","enrollment":90},{"nctId":"NCT03355157","phase":"PHASE4","title":"A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2018-03-01","conditions":"Metastatic Breast Cancer","enrollment":130},{"nctId":"NCT06616259","phase":"PHASE3","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","status":"NOT_YET_RECRUITING","sponsor":"Meng Qiu","startDate":"2024-09-26","conditions":"Colorectal Cancer (CRC), Capecitabine, Cetuximab","enrollment":452},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT06586294","phase":"PHASE1, PHASE2","title":"A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2024-09-10","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":294},{"nctId":"NCT06566755","phase":"PHASE3","title":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","status":"RECRUITING","sponsor":"Caigang Liu","startDate":"2024-02-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06176534","phase":"PHASE2","title":"Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-01-01","conditions":"Advanced Breast Cancer, Treatment, HR Low/HER2 Negative","enrollment":240},{"nctId":"NCT06555471","phase":"PHASE2","title":"A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-06","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT06506292","phase":"PHASE2","title":"A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-01","conditions":"Adebrelimab (SHR-1316), XELOX, GC/GEJC","enrollment":25},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT04891900","phase":"NA","title":"TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-05-10","conditions":"Gastric Cancer, Adenocarcinoma of Esophagogastric Junction","enrollment":25},{"nctId":"NCT02344472","phase":"PHASE3","title":"Detect V / CHEVENDO (Chemo vs. Endo)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2015-09","conditions":"Metastatic Breast Cancer","enrollment":271},{"nctId":"NCT05954078","phase":"PHASE3","title":"Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-08-01","conditions":"High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation","enrollment":340},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT06277050","phase":"PHASE3","title":"Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2024-03-07","conditions":"Nasopharyngeal Carcinoma, High-Risk Cancer, Maintenance Therapy","enrollment":264},{"nctId":"NCT05648006","phase":"PHASE2","title":"First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2023-10-17","conditions":"Advanced Colorectal Carcinoma","enrollment":7},{"nctId":"NCT04908813","phase":"PHASE2","title":"Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2021-09-29","conditions":"Gastric Cancer","enrollment":150},{"nctId":"NCT06202716","phase":"PHASE2","title":"Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT06259721","phase":"PHASE2","title":"Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2024-02-10","conditions":"Nasopharyngeal Carcinoma","enrollment":22},{"nctId":"NCT02918162","phase":"PHASE2","title":"Perioperative Chemo and Pembrolizumab in Gastric Cancer","status":"COMPLETED","sponsor":"Gulam Manji","startDate":"2017-11-25","conditions":"Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction","enrollment":49},{"nctId":"NCT03376659","phase":"PHASE1, PHASE2","title":"Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2018-08-08","conditions":"Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":8},{"nctId":"NCT06238752","phase":"PHASE2","title":"First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2021-03-01","conditions":"Advanced Gastric Adenocarcinoma","enrollment":33},{"nctId":"NCT05918094","phase":"PHASE3","title":"Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-04-30","conditions":"Gastric Cancer","enrollment":540},{"nctId":"NCT04395989","phase":"PHASE2","title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2020-07-28","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":139},{"nctId":"NCT06169202","phase":"","title":"A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2023-06-01","conditions":"Fruquintinib, Irinotecan, Capecitabine","enrollment":50},{"nctId":"NCT05360277","phase":"PHASE2","title":"Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Yanhong Deng","startDate":"2023-08-22","conditions":"Metastatic Colorectal Cancer，NED","enrollment":52},{"nctId":"NCT06158919","phase":"NA","title":"A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-11-20","conditions":"Gastric Cancer/Adenocarcinoma of Esophagogastric Junction","enrollment":58},{"nctId":"NCT03451370","phase":"","title":"First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2017-11-01","conditions":"Elderly Metastatic Colorectal Cancer Patients","enrollment":121},{"nctId":"NCT05262335","phase":"PHASE2","title":"Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-12-01","conditions":"Gastrointestinal Tumors","enrollment":116},{"nctId":"NCT05512520","phase":"PHASE2","title":"Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-09-20","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":126},{"nctId":"NCT04310176","phase":"PHASE2","title":"Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2019-05-24","conditions":"Ras-mutated Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT06115733","phase":"NA","title":"Study of Fuquinitinib Combined With Capecitabine First-line Maintenance in the Treatment of Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-12-28","conditions":"Colorectal Carcinoma","enrollment":56},{"nctId":"NCT05781958","phase":"PHASE2","title":"Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC","status":"UNKNOWN","sponsor":"Shen Feng","startDate":"2022-11-24","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":64},{"nctId":"NCT06094868","phase":"PHASE2","title":"Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2023-10","conditions":"Gastric Cancer","enrollment":45},{"nctId":"NCT06070740","phase":"PHASE2","title":"First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-11-01","conditions":"Gastrointestinal Neuroendocrine Carcinoma","enrollment":22},{"nctId":"NCT06055166","phase":"PHASE2","title":"A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2023-11-01","conditions":"PARP Inhibitor for Esophageal Squamous Cell Carcinoma","enrollment":120},{"nctId":"NCT05555901","phase":"PHASE2","title":"The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-06-18","conditions":"Metastatic Colorectal Cancer","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Maintenance Therapy with Capecitabine","genericName":"Maintenance Therapy with Capecitabine","companyName":"Jiangxi Provincial Cancer Hospital","companyId":"jiangxi-provincial-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is a prodrug that is converted to fluorouracil in tumor tissue, where it inhibits thymidylate synthase and gets incorporated into DNA and RNA to disrupt cancer cell growth. Used for Maintenance therapy for colorectal cancer (likely indication based on capecitabine use), Metastatic breast cancer, Gastric cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}